Research Reports

Official guidance

Mgmt quotes

“Innovation continues to be the foundation of our success.” (CEO)
“We expect 2026 to be another year powered by innovation, operational excellence, and strategic execution.” (CEO)
“This path [of price increases suppressing demand] is not sustainable long-term, so we began to make changes in the fourth quarter.” (CEO)
“With Aveir and investments in conduction system pacing..., we see the $10 billion rhythm management market as a great opportunity to capture market share.” (CEO)
“Our CGM sales have grown by more than a billion dollars for the third consecutive year.” (CFO)

Topic: 营收指引下调原因及营养业务展望
Key points:
- 2026年营收中点指引7%（低于此前共识7.5%），EPS指引10%与共识一致
- 营养业务Q4负增长，因消费者价格敏感导致销量下降，公司已启动价格促销；预计上半年营养业务增长承压，下半年恢复正增长
- 其他大部分业务（心血管、糖尿病、EPD、制药等）维持高个位数或低双位数增长，且诊断业务约十亿美元逆风将消退
Mgmt stance: 中性偏乐观（承认营养短期挑战，但认为6个月可调整，且其他业务强劲，整体EPS目标不变）

Topic: 电生理（EP）产品组合及战略进展
Key points:
- 三年前制定策略，即使无PFA产品仍维持双位数增长；现PFA产品Volt在欧洲上市顺利，美国有限市场发布反馈良好（整合映射、可镇静麻醉）
- 今年将推出Volt（美国）和Tactiflex Duo（国际），提供RF和PFA双能量源
- 25%的左心耳封堵术（LAA）同步进行，强调完整组合（导管、鞘、LAA装置）是领先关键
- 预期EP市场增长中高十几（mid-to-high teens），公司应与市场同步增长
Mgmt stance: 乐观（产品组合完整，团队执行力强，对今年增长有高期望）

Topic: CGM增长前景及市场渗透机会
Key points:
- 连续四年每年增加约10亿美元收入，2026年预计低十几增长（low-teens）
- 非胰岛素用户、基础胰岛素用户、强化胰岛素用户均有大量渗透空间；美国非胰岛素用户报销有望在上半年出现语言进展，但未计入指引
- 酮体监测产品（GKS传感器）可用于SGLT2用户（美国约600万用户，仅约100万使用CGM），可推动市场扩张和份额转换
- 国际市场强化胰岛素用户仅约50%渗透，仍有空间
Mgmt stance: 乐观（市场仍处于早期阶段，有大量增长机会，公司已做好准备）

Topic: Aveir起搏器渗透率及资本配置策略
Key points:
- 全球低电压起搏市场约50亿美元，Aveir目前约占10%份额；美国单腔起搏细分市场（占整体15%）约50%渗透
- Exact Sciences收购预计2月20日股东投票，Gross debt/EBITDA约2.7倍，近期重点整合，后续可进行小型补强并购；EPS稀释约20美分，时间表无变化
- 多癌早筛检测有望成为类似脂质面板的年度常规检测，前景广阔
Mgmt stance: 中性偏乐观（Aveir早期但成长可持续，收购整合推进中，资产负债表有充足容量）

Topic: 营养业务定价策略及盈利前景
Key points:
- 感恩节前在美国和国际进行了定价测试，美国早期结果鼓舞人心
- 营养业务盈利能力预计与2025年水平一致，通过调整支出结构（从品牌推广转向价格促销）维持稳定利润
- 需持续监测消费者反应和竞争活动
Mgmt stance: 中性（早期信号积极，但仍在监测中，未来6个月将保持稳定

Topic: Diagnostics China headwinds & diabetes coverage expansion
Key points:
- The bulk of VBP is done; next area (core lab oncology) has very low Abbott market share.
- Diagnostics global outlook: single-digit growth in 2026 vs 2025; excluding China, growth would be 7–8%.
- Diabetes: non-insulin type 2 coverage supported by ADA & CMS; expects some language in H1, but not baked into guidance.
Mgmt stance: Neutral-cautious on China (stable but not growing); bullish on diabetes long-term but not counting on near-term upside.

Topic: MedTech macro environment & 2026 growth trajectory
Key points:
- Q4 MedTech volumes were “really good” across all categories; mgmt would be “extremely surprised” if others report weak volumes.
- 2026 growth: Q1/first half likely in line with Q4 pace, then improving in second half (two-year stack shows acceleration).
- No indication of MedTech volume slowdown despite APA subsidy concerns.
Mgmt stance: Bullish — MedTech innovation and clinical evidence support attractive multi-year growth.